Fibroblast growth factor receptor 3
Synonyms: CD333, CEK2, JTK4, ACH
The fibroblast growth factor is a receptor tyrosine kinase signaling pathway that fundamentally regulates embryogenesis, angiogenesis, tissue homeostasis, and wound repair1. Alterations in FGFR signaling are associated with a broad range of congenital craniofacial developmental disorders, and somatic mutations of FGFR also have a role in oncologic evolution. FGFR3 is one of the 4 highly conserved transmembrane tyrosine kinase receptors. FGFR3 was shown to play role in role in several human disorders, including skeletal dysplasias, multiple myeloma, and cervical and bladder carcinomas2.
FGFR3 kinase assay is run on mobility shift microfluidics platform (Caliper), which provides best in industry quality of data. We routinely run services associated with this kinase including: screening, profiling, dose-response studies and kinetic measurements. Please contact us for more information.
1. Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017 Feb 28;8(9):16052.
2. Krejci P, Murakami S, Prochazkova J, Trantirek L, Chlebova K, Ouyang Z, Aklian A, Smutny J, Bryja V, Kozubik A, Wilcox WR. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. Journal of Biological Chemistry. 2010 Jul 2;285(27):20644-53.